Wednesday, August 23, 2017| Acquisitions, Mergers, Carl Zeiss Meditec, Nidek, Product Releases

EyewireTV — Retinal Imaging for Alzheimer’s; Zeiss Acquisition

In this week’s EyewireTV, a new study shows that noninvasive retinal imaging may detect the pathological hallmarks of Alzheimer’s disease; and Carl Zeiss Meditec acquires Veracity Innovations, maker of a cloud-based platform that provides eye doctors access to clinical data at each step in the treatment regimen. Also, Nidek announces the launch of the the TS-310, a tabletop subjective refraction system that combines refractor and chart capabilities in a compact footprint.

Watch Video

Wednesday, August 16, 2017

EyewireTV — Solar Eclipse Safety; Eyetube3D Launches

As Americans prepare for the first total solar eclipse in the United States in 37 years, EyewireTV provides tips on how to safely view the rare event and advice to physicians who may see patients with solar retinopathy; and a year after launching in the United States, Shire applies for European approval for its blockbuster dry eye drug lifitegrast. Also, Eyetube announces the launch of Eyetube3D, a new channel that allows physicians with a virtual reality headset to view 3-dimensional surgical cases online.

Watch Video

Wednesday, August 09, 2017| Cornea, FDA Approval/Clearance, Intraocular Pressure, IOP, Johnson & Johnson Vision Care, Meibomian Gland Dysfunction, MGD, Optovue, TearScience, Valeant

EyewireTV — J&J Agrees To Buy TearScience; FDA Clears Epi-Mapping Software

In this week’s EyewireTV, Johnson & Johnson Vision continues to boost its eye care portfolio as it announces a definitive agreement to acquire TearScience, a provider of devices that detect and treat meibomian gland dysfunction; and the FDA rejects Valeant's new drug application for IOP-lowering eye drop latanoprostene bunod, citing manufacturing issues. Also, the FDA clears Optovue's epithelial thickness mapping software (epi-mapping) for quantitative measurements of the epithelial and stromal layers of the cornea.

Watch Video

Wednesday, July 26, 2017| Dompé, Dry Eye, neurotrophic keratitis, TearLab Corp., TearLab Discovery System

EyewireTV - Dry Eye Disease Redefined; New TearLab Platform

In this week’s Eyewire, the Tear Film & Ocular Surface Society (TFOS) Dry Eye Workshop (DEWS) II report is published, updating the definition of dry eye disease; and TearLab receives CE Mark approval for its next-generation, in-vitro diagnostics testing platform, the TearLab Discovery System. Also, Dompé announces that the European Commission has granted marketing authorization of its cenegermin eye drops for the treatment of moderate to severe neurotrophic keratitis.

Watch Video

Wednesday, July 19, 2017| Alcon, Cataract Surgery, Contact Lenses & Solutions, Excimer Lasers, FDA Approval/Clearance, Hyperopia, Johnson & Johnson Vision Care, Novartis

EyewireTV — FDA Approves Hyperopia Indication for iDesign; Alcon Sales Increase

In this week’s EyewireTV, the FDA approves a new hyperopia treatment indication for Johnson & Johnson Vision’s Star S4 IR Excimer Laser System and iDesign System; and Alcon sales accelerate in the second quarter, which may have an impact on Novartis’ plans to spin-off the eye care division. Also, British surgeons find 27 contact lenses lodged in a woman’s eye while prepping her for cataract surgery.

Watch Video

Wednesday, July 12, 2017| Blepharoplasty, FDA Approval/Clearance, Glaucoma, Inotek Pharmaceuticals, Intraocular Pressure, IOP, IOPtima, Ocular Therapeutix

EyewireTV — FDA Rejects Dextenza Again; Blepharoplasty System Launched

In this week’s EyewireTV, for the second time, the FDA does not approve Ocular Therapeutix's NDA for Dextenza, citing manufacturing deficiencies; and IOPtima announces the launch of the iLid CO2 laser-assisted blepharoplasty kit. Also, in a phase 2 trial, Inotek Pharmaceuticals’ glaucoma candidate fails to show a clinical advantage in IOP reduction after 4 weeks.

Watch Video
Load More